Abstract

BackgroundSecukinumab, a fully human monoclonal antibody that selectively neutralises IL-17A, provided significant and sustained improvement in the signs and symptoms of active psoriatic arthritis (PsA) over 2 years in the...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
256 Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 4-year results from the Phase 3 FUTURE 2 study
Luminita Pricop ... Bruce Kirkham
Rheumatology | VOL. 58
Luminita Pricop, et. al.Luminita Pricop ... Bruce Kirkham
01 Apr 2019
AB0945 Secukinumab efficacy in patients with active psoriatic arthritis: pooled analysis of four phase 3 trials by prior anti-tnf therapy and concomitant methotrexate use
K Abrams ... B Kirkham
Annals of the Rheumatic Diseases | VOL. 77
K Abrams, et. al.K Abrams ... B Kirkham
01 Jun 2018
Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
Tom Wj Huizinga ... Kristel Luijtens
Arthritis research & therapy | VOL. 17
Tom Wj Huizinga, et. al.Tom Wj Huizinga ... Kristel Luijtens
15 Nov 2015
SAT0470 Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 3-year efficacy and safety results from phase 3 future 1 trial
H Tahir ... J Rech
Annals of the Rheumatic Diseases | VOL. 76
H Tahir, et. al.H Tahir ... J Rech
01 Jun 2017
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
Single-cell transcriptomes and chromatin accessibility of endothelial cells unravel transcription factors associated with dysregulated angiogenesis in systemic sclerosis
Mengqi Huang ... Robert Lafyatis
Annals of the Rheumatic Diseases | VOL. -
Mengqi Huang, et. al.Mengqi Huang ... Robert Lafyatis
16 May 2024
Remission and low disease activity are associated with lower healthcare costs: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort
Megan R W Barber ... Ann E Clarke
Annals of the Rheumatic Diseases | VOL. -
Megan R W Barber, et. al.Megan R W Barber ... Ann E Clarke
16 May 2024
Treatment of recalcitrant psoriasis and psoriatic arthritis with a combination of a biologic plus an oral JAK or TYK2 inhibitor: a case series
M Grace Hren ... Saakshi Khattri
Annals of the Rheumatic Diseases | VOL. -
M Grace Hren, et. al.M Grace Hren ... Saakshi Khattri
16 May 2024
News from EULAR
Yuliia Caliskan
Annals of the Rheumatic Diseases | VOL. 83
Yuliia CaliskanYuliia Caliskan
15 May 2024
View more papers